I would argue that the “personalized” care that geriatric oncologists are championing should be the future of oncology as much as the “precision” care of immune-based and targeted therapies.
The University of North Carolina has multiple posters accepted to the Gynecologic Oncology General Poster Session at this year’s ASCO meeting. Let’s take a virtual walk through several of these abstracts.
As a radiation oncologist in training with interests in multiple disease sites, geriatrics, and health services research, I find ASCO extremely educational, motivating, and often frustrating: There is absolutely no way to attend every session of interest.
This morning I attended the Annual PLATO Fellows Forum in Breast Oncology at ASCO. This is a fantastic venue in which oncology trainees can learn about cutting-edge breast cancer management strategies and the frontiers of research.
It’s Saturday morning, and ASCO is fully underway. I started the morning at the immense poster exhibit hall. Although it is easy to feel intimidated by the size of the room and number of posters, I find that walking the poster hall can actually be one of the most personal and intimate ways to experience the ASCO meeting.
Reports of women being criticized for “intense” workouts in late pregnancy are circulating the Web. Are these criticisms clinically warranted, or are the criticizers just bullies?
In an adolescent, polycystic ovary syndrome should be diagnosed cautiously. The typical symptoms of PCOS in an adult may just be developmental irregularities in a teen.
The tobacco industry has, in effect, caused the biggest toxic spill in history, one that has very literally killed millions of Americans. It is time that the courts compel the industry to clean up their mess.
Nationally, the number of drug shortages has tripled since 2005. Our county’s hospice agency has experienced shortages of liquid morphine, scopolamine patches, and medications to relieve nausea. Other generic drug shortages in our clinic have included paclitaxel, leucovorin, and doxorubicin. We have had limited ability to order fluorouracil (5-FU) and mitomycin.
Despite efforts by the manufacturer to reduce the cost of Avastin, the clinical effectiveness agency for England and Wales says that it will not recommend the drug for the first-line treatment of metastatic colorectal cancer.